During the last session, Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares were 0.52 million, with the beta value of the company hitting 0.74. At the end of the trading day, the stock’s price was $1.41, reflecting an intraday gain of 8.46% or $0.11. The 52-week high for the GALT share is $4.27, that puts it down -202.84 from that peak though still a striking 48.23% gain since the share price plummeted to a 52-week low of $0.73. The company’s market capitalization is $87.85M, and the average intraday trading volume over the past 10 days was 0.25 million shares, and the average trade volume was 744.96K shares over the past three months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
Galectin Therapeutics Inc (GALT) registered a 8.46% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.46% in intraday trading to $1.41, hitting a weekly high. The stock’s 5-day price performance is 7.63%, and it has moved by 10.16% in 30 days. Based on these gigs, the overall price performance for the year is -16.57%. The short interest in Galectin Therapeutics Inc (NASDAQ:GALT) is 7.98 million shares and it means that shorts have 20.72 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.30%. While earnings are projected to return 1.35% in 2025, the next five years will return -15.49% per annum.
GALT Dividends
Galectin Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Galectin Therapeutics Inc insiders own 31.24% of total outstanding shares while institutional holders control 16.05%, with the float percentage being 23.34%. VANGUARD GROUP INC is the largest shareholder of the company, while 111.0 institutions own stock in it. As of 2024-06-30, the company held over 2.12 million shares (or 3.4143% of all shares), a total value of $4.78 million in shares.
The next largest institutional holding, with 1.56 million shares, is of BLACKROCK INC.’s that is approximately 2.5232% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.53 million.
Also, the Mutual Funds coming in first place with the largest holdings of Galectin Therapeutics Inc (GALT) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.25 shares. This amounts to just over 1.99 percent of the company’s overall shares, with a $1.76 million market value. The same data shows that the other fund manager holds slightly less at 670.16, or about 1.07% of the stock, which is worth about $0.94 million.
